摘要
目的探究血清可溶性肿瘤坏死因子受体(soluble tumor necrosis factor receptor,sTNFR)与精神分裂症疗效的相关性。方法选取2018年3月~2019年8月到我院接受治疗的精神分裂症患者78例作为观察组,并选取与病例组人口特征无统计学差异的健康个体78例作为对照组。采用生物素双抗体夹心酶联免疫吸附法,检测所有患者的血清sTNFR1水平和sTNFR2水平,并采用PANSS量表评估精神分裂症患者组的精神病理症状,评估药物治疗后8周的疗效,进一步分析血清sTNFR对精神分裂症近期内治疗效果的影响。结果观察组精神分裂症患者血清内sTNFR1表达水平在治疗前后均高于健康对照组(P<0.05)。观察组精神分裂症患者血清内sTNFR2表达水平在治疗前后均低于健康对照组(P<0.05);观察组治疗后sTNFR1水平较治疗前有显著降低,趋向于对照组健康患者的血清sTNFR1表达水平,观察组治疗后sTNFR2水平较治疗前有显著升高,趋向于对照组健康患者的血清sTNFR2表达水平(P<0.05)。观察组精神分裂症患者sTNFR1与治疗前后PANSS阳性症状分及PANSS总分正相关(P<0.05),而sTNFR2水平与治疗前后阳性症状、阴性症状及PANSS总分均不相关(P>0.05)。观察组精神病患者对治疗前后产生不同效应组的血清sTNFR1和sTNFR2水平进行比较,显示有治疗效应组的血清sTNFR1和sTNFR2水平低于无治疗效应组,治疗后的两组血清sTNFR1水平具有统计学差异(P<0.05)。结论经过治疗后,血清sTNFR表达水平与精神分裂症状同步改善,血清sTNFR可能可以作为精神分裂症药物短期疗效标记物。
Objective To explore the correlation between serum sTNFR and the efficacy of schizophrenia;Methods 78 patients with schizophrenia who came to our hospital for treatment from March 2018 to August 2019 were selected as the observation group,and the demographics of the case group were selected 78 healthy individuals with no statistically different characteristics served as the control group.The biotin double antibody sandwich enzyme-linked immunosorbent assay was used to detect the serum sTNFR1 and sTNFR2 levels of all patients,and the PANSS scale was used to evaluate the psychopathological symptoms of the schizophrenia group,and to evaluate the efficacy of the drug in the short-term 8 weeks after treatment To further analyze the effect of serum sTNFR on the treatment effect of schizophrenia in the short term.Results The expression levels of sTNFR1 and sTNFR2 in the serum of patients with schizophrenia in the observation group were higher than those in the healthy control group before and after treatment(P<0.05).The level of sTNFR1 in the observation group after treatment was significantly lower than that before treatment,and tended to the expression level of serum sTNFR1 in healthy patients in the control group.The level of sTNFR2 in the observation group after treatment was significantly higher than that before treatment,and it tended to the expression level of serum sTNFR2 in healthy patients in the control group(P<0.05).In the observation group,sTNFR1 was positively correlated with the total score of PANSS positive symptoms before and after treatment and the total score of PANSS(P<0.05),while the level of sTNFR2 was not correlated with the total scores of positive symptoms,negative symptoms and PANSS before and after treatment(P>0.05).Comparison of serum sTNFR1 and sTNFR2 levels in the observation group with different effect groups before and after treatment showed that the serum sTNFR1 and sTNFR2 levels of the treatment-effect group were lower than those of the non-treatment-effect group,and the serum sTNFR1 le
作者
宋婧
李玉方
僧军燕
祝学莹
SONG Jing;LI Yufang;SENG Junyan(Department of Neurology,General Hospital of Pingmei Shenma Medical Group,Pingdingshan 467000,China)
出处
《国际精神病学杂志》
2022年第6期993-996,共4页
Journal Of International Psychiatry
